Top segments and regional performance

Last year, the company generated ‪3.37 B‬ USD, the most of which — ‪3.24 B‬ USD — came from its top-performing segment, Immunotherapy Technologies, compared to ‪2.98 B‬ USD the previous year. The greatest contribution came from United States, which accounted for ‪2.03 B‬ USD last year, with ‪2.00 B‬ USD the year before.